Christopher Downey

Christopher (Chris) Downey is a Review Chief in FDA/CDER’s Office of Biotechnology Products (OBP). He joined OBP in 2012, serving as a team leader from 2014-2017 and a review chief from 2017 to present. As a review chief in OBP’s Division of Biotechnology Review and Research IV (DBRR IV), Dr. Downey oversees CMC reviews of therapeutic proteins, including monoclonal antibody therapies. He received his PhD in Biochemistry from the University of Colorado at Boulder was a postdoctoral research at the University of Colorado and Georgetown University Medical Center.